

CLINICAL SCIENCE

Guidance for Authors 1998

CONTENTS

	<i>page</i>
1. Policy of the journal	
1.1. Scope	i
1.2. Availability on the World Wide Web (WWW)	i
1.3. The editorial process	i
1.4. Ethics of investigations	i
1.5. Originality of papers	ii
2. Submission of Manuscripts: General Information and Format	
2.1. General	ii
2.2. Use of authors' diskettes	ii
2.3. Full Papers	iii
2.4. Rapid Communications	iii
2.5. Correspondence	iii
2.6. Editorial Reviews	iv
2.7. Comments	iv
2.8. Arrangements for large amounts of information	iv
2.9. Proof corrections	iv
2.10. Offprints	iv
2.11. Availability on MEDLINE and from Adonis	iv
3. Miscellaneous Notes	
3.1. Abbreviations	iv
3.2. Anatomical nomenclature	iv
3.3. Animals, plants and micro-organisms	iv
3.4. Biochemical nomenclature	iv
3.5. Buffers and salts	iv
3.6. Computer modelling	iv
3.7. Doses	iv
3.8. Enzymes	iv
3.9. Evaluation of measurement procedures	v
3.10. Figures and Tables	v
3.11. Footnotes	v
3.12. 'Homology'	v
3.13. Isotope measurements	vi
3.14. Radionuclide applications in man	vi
3.15. Methods	vi
3.16. Nomenclature of disease	vi
3.17. Powers in Tables and Figures	vi
3.18. References	vi
3.19. Solutions	vi
3.20. Spectrophotometric data	vi
3.21. Spelling	vi
3.22. Statistics	vii
3.23. Trade names	vii
4. Units: The SI System	vii
5. Abbreviations, Conventions etc.	vii

I. POLICY OF THE JOURNAL

I.1. Scope

Clinical Science publishes papers in the field of clinical investigation, provided they are of a suitable standard and contribute to the advancement of knowledge in this field. The term 'clinical investigation' is used in its broadest sense to include studies in animals and the whole range of biochemical, physiological, immunological and other approaches that may have relevance to disease in man. Studies which are confined to normal subjects, or animals, or are purely methodological in nature may be acceptable. The material presented should permit conclusions to be drawn and should not be only of a preliminary nature. The journal publishes five types of manuscript, namely invited Editorial Reviews, Full Papers, Rapid Communications, Correspondence and invited Comments. In addition, *Clinical Science* publishes abstracts of the proceedings of the Medical Research Society (as Supplements) and also the Bayer Lecture.

I.2. Availability on the World Wide Web (WWW)

Abstracts of all articles are available on the journal's home page on the WWW (<http://cs.portlandpress.co.uk>). The journal will become fully online during 1998.

I.3. The editorial process

Membership of the Editorial Board covers as wide a range of interests as possible.

A submitted paper is considered by an appropriate editor together with (usually) two Referees from outside the membership of the Board. The Editor returns it with a recommendation to the Editor in Chief or Regional Editor, who then writes formally to the authors. The ultimate responsibility of acceptance for publication lies with the Editor in Chief.

Authors may suggest potential referees for their papers in the submission letter. The journal is under no obligation to follow such suggestions, but, if it does so, only one of the referees will be chosen from the authors' nominations, as the other referee will be selected independently.

I.4. Ethics of investigations

(a) Human subjects. Authors must state in the text of their paper that the research has been carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association, and has been approved by the Ethics Committee of the institution in which the work was performed. Consent **must** be obtained from each patient or subject after full explanation of the purpose, nature and risk of all procedures used, and the fact that such

Volume 94

AUTHOR INDEX

- Aalkjaer, C. 359–365
Abbott, M. 671–676
Adams, C. 121–127
Adams, M. 359–365
Åkerblom, H. K. 263–269
Akinola, A. 49–55
Aliot, E. 485–492
Andreu, A. L. 447–452
Arnal, M. 413–423
Arner, P. 71–77
Atherton, J. 339–346
Avkiran, M. 359–365
- Baandrup, U. 141–147
Badier, M. 279–286
Baines, M. 197–201
Balcke, P. 431–435
Ballinger, A. 479–483
Banning, A. P. 43–48
Bär, P. R. 271–278
Barber, C. 157–163
Barnes, P. J. 557–572
Barron, J. 591–599
Bauersachs, R. 255–261
Bayle, G. 413–423
Beck, O. 663–670
Beilin, L. J. 573–578
Belch, J. J. F. 537–540
Bell, J. I. 473–478
Bendahan, D. 279–286
Berlanga, J. 219–223
Bernardi, L. 615–621
Besser, R. 479–483
Bethune, D. W. 35–41
Beyer, J. 255–261
Blanco, I. 189–195
Bolinder, J. 71–77
Bone, J. M. 425–430
Bord, S. 549–555
Bottomley, M. J. 395–404
Boyer, J. 181–188
Brain, A. 203–206
Brenchley, P. E. C. 395–404
Brett, S. E. 129–134
Breuillé, D. 413–423
Bruda, N. L. 505–509
Brunini, T. M. C. 43–48
Bruntz, J. F. 485–492
Buckley, M. G. 591–599
Bund, S. J. 225–229, 231–238
Burrell, L. M. 517–523
- Butler, R. 175–180
Buus, N. H. 141–147
- Caballero, M. E. 219–223
Caillol, N. 181–188
Calder, A. G. 321–331
Calder, P. C. 303–311
Carney, B. I. 65–70
Chan, C.-C. 367–371
Chang, F.-Y. 367–371, 645–650
Charlesworth, J. A. 511–516
Chati, Z. 485–492
Chen, M.-F. 29–34
Cheng, Y.-R. 645–650
Childhood Diabetes in Finland Study Group 263–269
Chilvers, E. R. 461–471
Chowienczyk, P. J. 129–134
Chu, C.-J. 367–371
Ciuffo, R. 525–529
Clement, D. L. 57–63
Coghlan, J. P. 149–155
Condliffe, A. M. 461–471
Confort-Gouny, S. 279–286
Conway, M. 43–48
Cooke, R. W. I. 197–201
Costigan, M. 425–430
Cozzone, P. J. 279–286
Criado, M. 637–643
Critchley, M. 425–430
Croft, K. D. 573–578
- d'Annunzio, G. 615–621
Das, A. M. 493–504
Davis, J. 303–311
Davy, K. P. 579–584
Day, J. M. 671–676
De Buyzere, M. L. 57–63
de Dios, I. 293–301
De Jong, M. B. 271–278
Derckx, F. H. 165–173
DeSouza, C. A. 579–584
De Souza, G. 321–331
Devynck, M.-A. 79–85
Dhir, N. K. 87–99
Dimmitt, S. B. 573–578
Dodd, C. M. 541–547
Dodic, M. 149–155
Drieghe, B. 57–63
Drury, J. A. 197–201
- Duggan, K. A. 511–516
Duprez, D. A. 57–63
- Eiken, P. 405–412
Elder, J. B. 87–99
Elia, M. 313–319
Ellory, J. C. 43–48
Esler, M. D. 383–393
Esteller, A. 637–643
Ethévenot, G. 485–492
- Farthing, M. 479–483
Finch, C. F. 671–676
Flatebø, T. 453–460
Forst, T. 255–261
Fratino, P. 615–621
Frenneaux, M. P. 339–346
Fujii, T. 531–535
- Garcia, S. R. 225–229
García-Arumí, E. 447–452
Ghahary, A. 541–547
Gibson, P. R. 671–676
Gil-Martinez, E. 189–195
Gocke, C. 657–661
Goggins, M. 677–685
Grabietz, P. D. 271–278
Granado, F. 189–195
Green, L. 65–70
Griffin, G. E. 321–331
Grime, J. S. 425–430
Grouzmann, E. 591–599
Guha, S. 65–70
Guieu, R. 181–188
Guillot, C. 279–286
- Haenen, J. H. 651–656
Hallyburton, E. 479–483
Hamada, M. 21–27
Hambleton, I. 111–120
Hanssen, H. 43–48
Harm, F. 431–435
Harrap, S. B. 337–338
Hauser, A.-C. 431–435
Hayashi, Y. 585–590
Hellström, P. M. 663–670
Henney, A. 103–110
Hill, G. E. 505–509
Hirata, K. 531–535
Hirose, H. 633–636
Hiwada, K. 21–27

- Hjemdahl, P. 663–670
Hodge, G. 511–516
Holland, S. 203–206
Horowitz, M. 65–70
Hou, M.-C. 645–650
Hsu, H.-C. 29–34
Huang, Y.-T. 645–650
Hughes, A. 425–430
Humphries, S. 103–110
Hung, J. 437–445
Hunt, J. V. 35–41
Hurlbert, B. J. 505–509
- Ilonen, J. 263–269
Ilton, M. K. 437–445
Imms, F. J. 353–358
Iqbal, S. J. 203–206
Iribu, G. 585–590
Iyawe, V. I. 353–358
- Jackson, M. J. 1
James, L. A. 313–319
James, M. A. 245–253
Jammes, Y. 279–286
Janssen, M. C. H. 651–656
Jenkins, B. S. 129–134
Jennings, G. L. 383–393
Jewell, D. P. 473–478
Johansen, B. 453–460
Johnston, C. I. 517–523
Jonason, T. 239–243
Jones, K. L. 65–70
Jones, P. P. 579–584
Jordan, J. 5
- Kahr, O. 359–365
Kaiser, M. 359–365
Kakkar, R. 623–632
Kalra, J. 623–632
Kanazawa, H. 531–535
Kangawa, K. 21–27, 135–139, 585–590
Kawai, T. 633–636
Kawakami, H. 21–27
Kelly, M. 359–365
Kelly, P. 479–483
Kerckhoffs, D. A. J. M. 71–77
Kilias, D. 671–676
King, P. 157–163
Kirk, G. 537–540
Kitchen, E. 461–471
Kneale, B. J. 129–134
Knip, M. 263–269
Kojima, S. 135–139
Kolthoff, N. 405–412
Komulainen, J. 263–269
Kon, M. 271–278
Kong, M.-F. 157–163
- Kosakai, Y. 585–590
Kristensen, B. 405–412
Kroese, A. B. A. 271–278
Kröger, K. 657–661
Kudoh, S. 531–535
Kuneš, J. 79–85
Kunt, T. 255–261
Kuramochi, M. 135–139
Kuro, M. 585–590
Kurpad, A. V. 321–331
Küstner, E. 255–261
- Lambert, G. W. 383–393
Langley-Evans, S. C. 373–381
Le Quan Sang, K. H. 79–85
Lean, M. E. J. 121–127
Lee, C.-M. 29–34
Lee, D.-Y. 367–371
Lee, F.-Y. 645–650
Lee, S.-D. 367–371, 645–650
Lee, Y.-T. 29–34
Leen, E. 121–127
Leppert, J. 239–243
Leuzzi, S. 615–621
Levieux, D. 413–423
Lin, H.-C. 367–371, 645–650
Lind, L. 601–607
Lodos, J. 219–223
Lodwick, D. 359–365
Lombardo, D. 181–188
Loon, N. R. 287–292
López-Hellín, J. 447–452
López-Novoa, J. M. 637–643
Lord, R. 101
Lördal, M. 663–670
Lorini, R. 615–621
Lounamaa, R. 263–269
Lunn, P. G. 313–319
Lye, M. 493–498
- Macallan, D. C. 321–331
Macdonald, I. A. 157–163
MacGregor, G. A. 591–599
Mahadeva, N. 359–365
Makarious, M. M. 511–516
Maltby, P. 425–430
Mann, G. E. 43–48
Manso, M. A. 293–301
Mantha, S. V. 623–632
Maple, C. 537–540
Marshall, J. M. 111–120
Martín de Arriba, A. 637–643
Maruyama, H. 633–636
Mas, E. 181–188
Mathias, C. J. 49–55
Matsuo, H. 21–27, 135–139, 585–590
Matsuoka, H. 135–139
- May, C. N. 149–155
McFadden, E. R. 525–529
McKenna, W. J. 339–346
McLaren, M. 537–540
McNurlan, M. A. 321–331
Melsom, M. N. 453–460
Mendes Ribeiro, A. C. 43–48
Michielsen, W. 57–63
Middleton, S. 313–319
Millan, I. 189–195
Millgård, J. 601–607
Minamino, N. 21–27, 585–590
Misso, N. L. A. 437–445
Missouris, C. G. 591–599
Miyata, A. 135–139, 585–590
Mohamed-Ali, V. 609–614
Mohan, J. 111–120
Morris, A. D. 175–180
Morris-Thurgood, J. 339–346
Mulvany, M. J. 141–147
- Nakamura, K. 633–636
Nelson, J. A. 525–529
Newsholme, E. A. 303–311
Nicolaysen, G. 453–460
Nielsen, S. P. 405–412
Nishikimi, T. 135–139, 585–590
Nyborg, N. C. B. 141–147
Nycyk, J. A. 197–201
- Obled, C. 413–423
Olmedilla, B. 189–195
Oreffo, R. O. C. 549–555
Orfao, A. 293–301
- Paganga, G. 129–134
Pala, H. 303–311
Panerai, R. B. 245–253
Parkes, M. 473–478
Parkin, H. 157–163
Pasqualini, E. 181–188
Penny, M. 203–206
Peters, A. M. 7–19
Petyaev, I. M. 35–41
Pfütznern, A. 255–261
Phillips, P. A. 517–523
Playford, R. J. 219–223
Pohlmann, T. 255–261
Potter, J. F. 245–253
Prasad, K. 623–632
Pribasniĝ, A. 431–435
Puvi-Rajasingham, S. 49–55
- Radaelli, A. 615–621
Radhi, J. 623–632
Rambourdin, F. 413–423
Ramirez, D. 219–223
Reid, H. L. 111–120
Reijonen, H. 263–269

- Reynolds, T. M. 203–206
 Ringqvist, Å. 239–243
 Ringqvist, I. 239–243
 Risvanis, J. 517–523
 Ritter, J. M. 129–134
 Roberts, N. B. 43–48
 Robertson, D. 5
 Rodríguez-López, A. M. 637–643
 Rojas-Hidalgo, E. 189–195
 Rosella, O. 671–676
 Rudofsky, G. 657–661
 Russo, F. 353–358
 Rustom, R. 425–430
- Sabbah, E. 263–269
 Saito, I. 633–636
 Salvan, A. M. 279–286
 Salvucci, F. 615–621
 Samani, N. J. 359–365
 Sánchez-Rodríguez, A. 637–643
 Saruta, T. 633–636
 Satsangi, J. 473–478
 Savage, M. W. 609–614
 Scaramuzza, A. 615–621
 Schalekamp, M. A. 165–173
 Schelo, C. 657–661
 Schenk, U. 255–261
 Schragger, J. 87–99
 Schwartz, S. 447–452
 Scott, J. M. 677–685
 Scott, P. G. 541–547
 Seals, D. R. 579–584
 Segal, M. B. 353–358
 Serjeant, G. R. 111–120
 Shannon, J. R. 5
 Sheldon, R. S. 335–336
 Shen, Y. J. 541–547
 Shenkin, A. 425–430
 Sherman, R. C. 373–381
- Shetty, P. S. 321–331
 Shigematsu, Y. 21–27
 Shimada, Y. 359–365
 Shoji, S. 531–535
 Shovlin, C. L. 207–218
 Sidebotham, R. L. 87–99
 Sinclair, A. 121–127
 Singer, D. R. J. 591–599
 Skowronski, M. E. 525–529
 Smith, G. D. P. 49–55
 Smith, P. 359–365
 Spencer, J. 87–99
 Stewart, D. J. 3–4
 Struthers, A. D. 175–180
- Taberbero, M. D. 293–301
 Taes, Y. 57–63
 Tai, C.-C. 367–371
 Takishita, S. 135–139, 585–590
 Tattersall, R. B. 157–163
 Taylor, M. L. 437–445
 Ten Harkel, A. D. J. 347–352
 Terp, K. 141–147
 Thien, Th. 651–656
 Thies, F. 303–311
 Thomas, P. W. 111–120
 Thompson, J. M. 383–393
 Thompson, P. J. 437–445
 Thomson, H. L. 339–346
 Tonkin, A. 65–70
 Torres, A. 219–223
 Tredget, E. E. 541–547
 Triffitt, J. T. 549–555
 Tsai, Y.-T. 645–650
- Vähäsalo, P. 263–269
 Valenzuela, C. 219–223
 Valette, A. 181–188
 van Asten, W. N. J. C. 651–656
- van der Heijden, E. P. A. 271–278
 Vanhaverbeke, F. 57–63
 Van Lieshout, J. J. 347–352
 Veale, D. 537–540
 Vicente, S. 293–301
 Vuylsteke, A. 35–41
- Walker, M. M. 87–99
 Wallén, H. 663–670
 Walley, T. 493–498
 Wallin, B. G. 383–393
 Walsh, K. M. 121–127
 Wang, S.-S. 367–371
 Watson, C. J. 395–404
 Webb, N. J. A. 395–404
 Weimar, W. 165–173
 Weir, D. G. 677–685
 Werker, P. M. N. 271–278
 Wieling, W. 347–352
 Wiesholzer, M. 431–435
 Wilcox, C. S. 287–292, 687
 Williams, G. 609–614
 Williams, P. D. 573–578
 Wintour, E. M. 149–155
 Wishart, J. M. 65–70
 Wollersheim, H. 651–656
 Wu, S.-L. 367–371
- Yamada, M. 531–535
 Yaqoob, P. 303–311
 Ye, S. 103–110
 Yoshikawa, J. 531–535
 Yoshikawa, T. 531–535
 Yoshitomi, Y. 135–139
 Young, G. P. 671–676
- Zannad, F. 485–492
 Zicha, J. 79–85
 Zietse, R. 165–173

Volume 94

SUBJECT INDEX

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Reviews.

- Acetylcholine**
coronary arteries, hypertension 231–238
endothelial dysfunction, hypercholesterolaemia 129–134
neurovascular stimulation, diabetic neuropathy 255–261
- N*-Acetyl- β -D-glucosaminidase**
proteinuria, lisinopril 425–430
- Acquired immunodeficiency syndrome**
leptin, anorexia 479–483
- Acute phase proteins**
infection, protein metabolism 413–423
- Adenosine deaminase deficiency**
polymorphism, haemorrhagic telangiectasia 207–218*
- S*-Adenosylhomocysteine**
brain, protein carboxymethylation 677–685
- S*-Adenosylmethionine**
brain, protein carboxymethylation 677–685
- Adhesion**
platelet P-selectin, neutrophil cathepsin G 437–445
- Adhesion molecule-1**
inflammatory response, circadian rhythm 537–540
- Adipose tissue**
lipolysis, glucose metabolism 71–77
- Adolescents**
diabetes, cardiovascular reflexes 615–621
haematopoiesis, leptin 633–636
- Adrenaline**
isometric exercise, muscle sympathetic activity 383–393
thermogenesis, energy expenditure 121–127
- Adrenomedullin**
cardiac surgery, anaesthesia 585–590
gene expression, cardiac hypertrophy 359–365
hypertrophic cardiomyopathy, natriuretic peptides 21–28
myocardial infarction, natriuretic peptides 135–139
- Aerobic exercise**
heart rate variability, aging 579–584
- Aging**
aerobic exercise, heart rate variability 579–584
osteogenesis, colony forming units-fibroblastic 549–555
- Airway obstruction**
cold exposure, asthma 525–529
- Airway occlusion**
pulmonary blood flow distribution, blood gases 453–460
- Albumin**
bile-salt-dependent lipase, glycation 181–188
- Alkaline phosphatase**
colonic epithelium, butyrate enema 671–676
hypophosphatasia, pyridoxal-5'-phosphate 203–206
- Ammonia excretion**
proteinuria, lisinopril 425–430
- Anabolic block**
tuberculosis, undernutrition 321–331
- Anaesthesia**
adrenomedullin, cardiac surgery 585–590
- Angiotensin-converting enzyme**
glomerular permeability, diabetes 165–173
- Angiotensin-converting enzyme inhibitors**
diabetic nephropathy, hypertension 511–516
maternal undernutrition, hypertension 337–338, 373–381
proximal tubular hypercatabolism, lisinopril 425–430
- Anorexia**
acquired immunodeficiency syndrome, leptin 479–483
- Antioxidant enzyme activity**
oxidative stress, elderly 447–452
- Antioxidant enzymes**
diabetes, liver 623–632
- Antioxidant status**
preterm infants, lipid peroxidation 197–201
- Antioxidants**
diabetes, dietary supplements 189–195
hypercholesterolaemia, coronary artery disease 129–134
low-density lipoprotein, β -blockers 573–578

- Aprotinin**
 cardiopulmonary bypass, nitric oxide 505–509
 renal tubular injury, lisinopril 425–430
- L-Arginine**
 endothelial dysfunction, hypercholesterolaemia 129–134
- L-Arginine transport**
 erythrocytes, heart failure 3–4, 43–48
- Asthma**
 cold exposure, airway reactivity 525–529
 glucocorticoids, gene transcription 557–572*
- Atherosclerosis**
 diabetes, glycation 181–188
 vascular matrix remodelling, matrix metalloproteinases 103–110*
- Athymic mice**
 colon cancer, fish oil 303–311
- ATP synthase**
 mitochondrion, heart muscle 499–504
- Atrial natriuretic peptide**
 adrenomedullin, myocardial infarction 135–139
 cardiac hypertrophy, gene expression 359–365
 glomerular permeability, diabetes 165–173
 heart failure 591–599
 hypertrophic cardiomyopathy, adrenomedullin 21–28
- Atrial pacing**
 myocardial ischaemia, thromboxane 29–34
- Autoantibodies**
 diabetes, genetic susceptibility 263–269
- Autonomic failure**
 blood pressure, exercise 5, 49–55
 orthostatic hypotension 347–352
- Autonomic neuropathy**
 diabetes, baroreflex sensitivity 615–621
- β -blockers**
 low-density lipoprotein, oxidation 573–578
- Baroreflex sensitivity**
 diabetes, autonomic neuropathy 615–621
 hypertension, elderly 245–253
- Bile-salt-dependent lipase**
 albumin, glycation 181–188
- Blood clotting**
 platelets, vascular endothelial growth factor 395–404
- Blood flow**
 nitric oxide, insulin sensitivity 175–180
- Blood gases**
 bronchial occlusion, pulmonary flow distribution 453–460
- Blood pressure**
 baroreflex sensitivity, pressoreceptors 245–253
- captopril, maternal undernutrition 337–338, 373–381
 chronic fatigue syndrome, heart rate variability 57–63
 endothelium-dependent vasodilatation, noradrenaline 601–607
 gastric emptying, diabetes mellitus 65–70
 glucocorticoids, prenatal exposure 149–155
 insulin resistance, hypertension 609–614
 sympathetic denervation, exercise 5, 49–55
- Blood specimens**
 factitious hyperkalaemia 101
- Body cooling**
 flow-mediated dilatation, Raynaud's disease 239–243
- Body fat**
 acquired immunodeficiency syndrome, leptin 479–483
- Body mass index**
 insulin, leptin 633–636
- Bone**
 osteoprogenesis, aging 549–555
- Bone mineral density**
 lactation, pregnancy 405–412
- Brachial artery**
 endothelium-dependent dilatation, Raynaud's disease 239–243
- Brain blood flow**
 hyperventilation, isometric exercise 353–358
- Brain**
 hypoglycaemia, lactate 157–163
 protein carboxymethylation 677–685
- Brain natriuretic peptide**
 adrenomedullin, myocardial infarction 135–139
 heart failure 591–599
 hypertrophic cardiomyopathy, adrenomedullin 21–28
- Bronchial occlusion**
 pulmonary flow distribution, blood gases 453–460
- Bronchoalveolar lavage fluid**
 interstitial lung disease, cytokeratins 531–535
- Bumetanide**
 natriuretic response, metabolic alkalosis 287–292, 687
- Burns**
 hypertrophic scar tissue, proteoglycans 541–547
- Butyrate enema**
 colonic epithelium, cell proliferation 671–676
- Calcium**
 hypertension, membrane microviscosity 79–85

- Calcium intake
 - bone mineral density, pregnancy 405–412
- Calcium ions
 - ATP synthase, heart muscle 499–504
- Captopril
 - maternal undernutrition, hypertension 337–338, 373–381
- Carbohydrate ingestion
 - lipolysis, adipose tissue 71–77
- Carbon tetrachloride
 - hepatic injury, epidermal growth factor 219–223
- Carboxymethylation
 - protein, brain 677–685
- Cardiac baroreflex sensitivity
 - aerobic exercise, aging 579–584
- Cardiac hypertrophy
 - adrenomedullin, gene expression 359–365
- Cardiac output
 - obesity, adrenaline 121–127
 - orthostatic hypotension, autonomic failure 347–352
- Cardiac surgery
 - adrenomedullin, anaesthesia 585–590
 - oxygen, plasma lipid 1, 35–41
- Cardiopulmonary bypass
 - adrenomedullin, anaesthesia 585–590
 - lipid-associated oxygen, blood 1, 35–41
 - nitric oxide, aprotinin 505–509
- Cardiovascular reflexes
 - diabetes, adolescents 615–621
- Cardiovascular response
 - obesity, thermogenesis 121–127
- Carotenoids
 - diabetes, dietary supplements 189–195
- Catalase
 - diabetes, oxidative stress 623–632
 - oxidative stress, elderly 447–452
- Catecholamines
 - heart failure 591–599
- Cathepsin
 - oxidative stress, elderly 447–452
- Cathepsin G
 - platelet–neutrophil adhesion, platelet P-selectin 437–445
- Cell proliferation
 - colonic epithelium, butyrate enema 671–676
- Cerebral blood flow
 - isometric exercise, hyperventilation 353–358
- Cerebral dysfunction
 - diabetes, lactate 157–163
- Chronic atrophic gastritis
 - mucins 87–99
- Chronic fatigue syndrome
 - heart rate variability, blood pressure 57–63
- Chronic ischaemic myocardial remodelling
 - N*^G-nitro-L-arginine, coronary arteries 141–147
- Chronic lung disease
 - total antioxidant status, preterm infants 197–201
- Circadian rhythm
 - adhesion molecule-1, inflammatory response 537–540
- Circulatory reflex adjustment
 - orthostatic hypotension, autonomic failure 347–352
- Cirrhosis
 - nitric oxide, peripheral vascular resistance 637–643
 - portal hypertension, octreotide 367–371
- Clinical characteristics
 - diabetes, genetic susceptibility 263–269
- Cold exposure
 - airway obstruction, asthma 525–529
- Cold storage
 - muscle contractility, preservation solutions 271–278
- Colon cancer
 - fish oil, athymic mice 303–311
- Colonic epithelium
 - cell proliferation, butyrate enema 671–676
- Colony forming units-fibroblastic
 - osteogenesis, aging 549–555
- Colour Doppler sonography
 - venous thrombosis 657–661
- Congestive heart failure
 - adrenomedullin, natriuretic peptides 135–139
- Cooling
 - sickle cell disease, vascular response 111–120
- Coronary arteries
 - hypertension, acetylcholine 231–238
 - myocardial hypertrophy, nitric oxide 141–147
 - myogenic tone, nitric oxide 225–229
- Coronary artery disease
 - stromelysin expression, polymorphism 103–110*
 - vitamin E, hypercholesterolaemia 129–134
- Coronary disease
 - low-density lipoprotein, β -blockers 573–578
- Coronary flow reserve
 - exercise capacity, dilated cardiomyopathy 485–492
- Crohn's disease
 - genetic susceptibility, major histocompatibility complex 473–478*
- Cyclic GMP
 - endothelium-dependent dilatation, Raynaud's disease 239–243

- Cyclo-oxygenase
myogenic tone, hypertension 225–229
- Cytokeratins
bronchoalveolar lavage fluid, interstitial lung disease 531–535
- Decorin
hypertrophic scar tissue, fibroblasts 541–547
- Deep venous thrombosis
strain-gauge plethysmography, duplex scanning 651–656
- Deoxycorticosterone acetate-salt hypertension
vasopressin receptors 517–523
- Diabetes
adolescents, cardiovascular reflexes 615–621
bile-salt-dependent lipase, glycation 181–188
cerebral dysfunction, lactate 157–163
fat-soluble vitamins, dietary supplements 189–195
genetic susceptibility, autoantibodies 263–269
glomerular permeability, angiotensin-converting enzyme 165–173
neurovascular stimulation, nutritive capillary blood flow 255–261
oxidative stress, liver 623–632
postprandial hypotension, gastric emptying 65–70
- Diabetic nephropathy
angiotensin-converting enzyme 165–173
angiotensin-converting enzyme inhibitors, hypertension 511–516
neurogenic inflammation, total skin blood flow 255–261
- Dietary lipids
tumour growth, colon cancer 303–311
- Dietary supplements
fat-soluble vitamins, diabetes 189–195
- Dilated cardiomyopathy
coronary flow reserve, exercise capacity 485–492
- Diphenylhexatriene anisotropy
membrane microviscosity, erythrocytes 79–85
- Direct electrical stimulation
muscle contractility, preservation solutions 271–278
- Duplex scanning
deep venous thrombosis, strain-gauge plethysmography 651–656
- Elderly
hypertension, baroreflex sensitivity 245–253
lymphocytes, oxidative stress 447–452
temperature, haemodynamics 493–498
- Endoglin
genetic mutation, haemorrhagic telangiectasia 207–218*
- Endothelial dysfunction
vitamin E, hypercholesterolaemia 129–134
- Endothelin-1
hypertrophic cardiomyopathy, adrenomedullin 21–28
- Endothelium-dependent relaxation
coronary arteries, hypertension 231–238
vascular smooth muscle, nitric oxide 225–229
- Endothelium-dependent vasodilatation
hypertension, noradrenaline 601–607
Raynaud's disease, nitric oxide 239–243
- Endothelium-derived hyperpolarizing factor
coronary arteries, hypertension 231–238
- Endotoxin
cirrhosis, nitric oxide 637–643
- Energy expenditure
thermogenesis, adrenaline 121–127
- Epidermal growth factor
hepatic injury, carbon tetrachloride 219–223
- Erythrocytes
L-arginine transport, heart failure 3–4, 43–48
membrane microviscosity, hypertriglyceridaemia 79–85
- E-selectin
inflammatory response, circadian rhythm 537–540
- Excitation–contraction coupling
hypoxaemia, muscle fatigue 279–286
- Exercise
heart rate variability, aging 579–584
sympathetic denervation, blood pressure 5, 49–55
- Exercise capacity
coronary flow reserve, dilated cardiomyopathy 485–492
- Exercise-induced hypotension
venous capacitance, hypertrophic cardiomyopathy 335–336, 339–346
- Factitious hyperkalaemia
blood specimens 101
- Fasting
autonomic failure, blood pressure 5, 49–55
- Fat-soluble vitamins
diabetes, dietary supplements 189–195
- Fatty acids
tumour growth, colon cancer 303–311
- Fetal exposure
low-protein diet, hypertension 337–338, 373–381

- Fibroblasts**
hypertrophic scar tissue, decorin 541–547
- Fish oil**
colon cancer, athymic mice 303–311
- Flow-mediated dilatation**
Raynaud's disease, body cooling 239–243
- Free-radical production**
preterm infants, antioxidant status 197–201
- Gas-exchange abnormality**
bronchial occlusion, pulmonary flow distribution 453–460
- Gastric carcinoma**
mucins 87–99
- Gastric emptying**
postprandial hypotension, diabetes mellitus 65–70
- Gastrointestinal motility**
small intestine, 5-hydroxytryptamine 663–670
- Gastrointestinal tract**
Crohn's disease, genetic linkage 473–478*
glutaminase distribution, glutamine synthetase 313–319
- Gene expression**
adrenomedullin, cardiac hypertrophy 359–365
- Gene transcription**
glucocorticoids, inflammation 557–572*
vasopressin receptors, deoxycorticosterone acetate-salt hypertension 517–523
- Genetic linkage**
inflammatory bowel disease, Crohn's disease 473–478*
- Genetic mutation**
adenosine deaminase deficiency, respiratory disease 207–218*
- Genetic susceptibility**
Chron's disease, major histocompatibility complex 473–478*
diabetes, autoantibodies 263–269
- Glomerular angiotensin-converting enzyme activity**
angiotensin-converting enzyme inhibitors, diabetic nephropathy 511–516
- Glomerular permeability**
diabetes, angiotensin-converting enzyme 165–173
- Glucocorticoids**
inflammation, gene transcription 557–572*
prenatal exposure, hypertension 149–155
- Glucose metabolism**
adipose tissue, lipolysis 71–77
- Glucose tolerance test**
hypertension, insulin resistance 609–614
- Glucose uptake**
N^G-monomethyl-L-arginine, nitric oxide synthase 175–180
- Glutaminase distribution**
gastrointestinal tract, glutamine synthetase 313–319
- Glutamine**
gastrointestinal tract, glutamine synthetase 313–319
- Glutamine synthetase**
gastrointestinal tract, glutaminase distribution 313–319
- Glutathione peroxidase**
diabetes, oxidative stress 623–632
oxidative stress, elderly 447–452
- Glycation**
bile-salt-dependent lipase, albumin 181–188
- Glycopolypeptides**
gastric carcinoma 87–99
- Granulocyte pool**
pulmonary circulation, lung 7–19*
- Gut**
glutaminase distribution, glutamine synthetase 313–319
- Haematopoiesis**
leptin, adolescents 633–636
- Haemodiafiltration**
body mass index, leptin 431–435
- Haemodialysis**
obesity, leptin 431–435
- Haemodynamics**
portal hypertension, octreotide 645–650
temperature, elderly 493–498
- Haemorrhagic telangiectasia**
adenosine deaminase deficiency, polymorphism 207–218*
- Head-up tilt**
temperature, haemodynamics 493–498
- Heart failure**
adrenomedullin, gene expression 359–365
L-arginine transport, erythrocytes 3–4, 43–48
coronary flow reserve, exercise capacity 485–492
natriuretic peptides,
renin-angiotensin-aldosterone system 591–599
- Heart muscle**
ATP synthase, mitochondrion 499–504
- Heart rate variability**
aerobic exercise, aging 579–584
chronic fatigue syndrome, blood pressure 57–63
diabetes, adolescents 615–621

- Hepatic injury
carbon tetrachloride, epidermal growth factor 219–223
- High-density lipoprotein
oxidation, β -blockers 573–578
- High-flux haemodialysis
body mass index, leptin 431–435
- HLA-DQB1 alleles
diabetes, genetic susceptibility 263–269
- 5-Hydroxytryptamine
small intestine, gastrointestinal motility 663–670
- Hypercholesterolaemia
vitamin E, endothelial dysfunction 129–134
- Hyperdynamic circulation
portal hypertension, octreotide 645–650
- Hyperinsulinaemia
hypertension, blood pressure 609–614
- Hypertension
angiotensin-converting enzyme inhibitor, maternal undernutrition 337–338, 373–381
angiotensin-converting enzyme inhibitors, diabetic nephropathy 511–516
baroreflex sensitivity, elderly 245–253
coronary arteries, acetylcholine 231–238
endothelium-dependent vasodilatation, noradrenaline 601–607
glucocorticoids, prenatal exposure 149–155
insulin resistance, blood pressure 609–614
membrane microviscosity, calcium 79–85
myogenic tone, nitric oxide 225–229
vasopressin receptors 517–523
- Hypertriglyceridaemia
membrane microviscosity, erythrocytes 79–85
- Hypertrophic cardiomyopathy
adrenomedullin, natriuretic peptides 21–28
venous capacitance, hypotension 335–336, 339–346
- Hypertrophic scar tissue
fibroblasts, decorin 541–547
- Hyperventilation
isometric exercise, cerebral blood flow 353–358
- Hypoglycaemia
cerebral dysfunction, lactate 157–163
- Hypophosphatasia
alkaline phosphatase, pyridoxal-5'-phosphate 203–206
- Hypotension
gastric emptying, diabetes mellitus 65–70
venous capacitance, hypertrophic cardiomyopathy 335–336, 339–346
- Hypoxaemia
muscle fatigue, ^{31}P magnetic resonance spectroscopy 279–286
- Hypoxia
bronchial occlusion, pulmonary blood flow distribution 453–460
- Idiopathic pulmonary fibrosis
bronchoalveolar lavage fluid, cytokeratins 531–535
- Immune response
neutrophil priming, superoxide anions 461–471*
- Immunoassay
vascular endothelial growth factor 395–404
- Immunodeficiency
adenosine deaminase deficiency, genetic mutation 207–218*
- Indomethacin
myogenic tone, hypertension 225–229
- Infection
protein metabolism, acute phase proteins 413–423
- Inflammation
diabetic neuropathy, total skin blood flow 255–261
glucocorticoids, gene transcription 557–572*
neutrophil priming, phosphoinositide 3-kinase 461–471*
- Inflammatory bowel disease
genetic susceptibility, Crohn's disease 473–478*
leptin, body fat 479–483
- Inflammatory response
adhesion molecule-1, circadian rhythm 537–540
- Insulin
leptin, body mass index 633–636
- Insulin resistance
blood pressure, hypertension 609–614
- Insulin sensitivity
nitric oxide, blood flow 175–180
- Interstitial lung disease
bronchoalveolar lavage fluid, cytokeratins 531–535
- Intestinal-type metaplasia
mucins 87–99
- Intrauterine factors
hypertension, captopril 337–338, 373–381
- Intraventricular haemorrhage
total antioxidant status, preterm infants 197–201
- Ischaemia
muscle contractility, preservation solutions 271–278

- Isometric exercise**
 hyperventilation, cerebral blood flow 353–358
 muscle sympathetic activity, adrenaline 383–393
- Isosorbide dinitrate**
 portal hypertension, haemodynamics 645–650
- Kidney vasopressin receptors**
 deoxycorticosterone acetate-salt hypertension, gene transcription 517–523
- Lactate**
 diabetes, cerebral dysfunction 157–163
- Lactate extraction**
 myocardial ischaemia, atrial pacing 29–34
- Lactate metabolism**
 skeletal muscle, carbohydrate ingestion 71–77
- Lactation**
 bone mineral density 405–412
- Leptin**
 acquired immunodeficiency syndrome, anorexia 479–483
 haematopoiesis, adolescents 633–636
 obesity, haemodialysis 431–435
- Linkage studies**
 adenosine deaminase deficiency, haemorrhagic telangiectasia 207–218*
- Lipid**
 cardiopulmonary bypass, oxygen 1, 35–41
- Lipid-associated oxygen**
 cardiac surgery, blood 1, 35–41
- Lipid peroxidation**
 coronary disease, β -blockers 573–578
 preterm infants, antioxidant status 197–201
- Lipolysis**
 adipose tissue, glucose metabolism 71–77
- Lisinopril**
 proteinuria, renal tubular injury 425–430
- Liver**
 oxidative stress, diabetes 623–632
- Liver damage**
 carbon tetrachloride, epidermal growth factor 219–223
- Liver vasopressin receptors**
 deoxycorticosterone acetate-salt hypertension, gene transcription 517–523
- Loop diuretics**
 natriuretic response, metabolic alkalosis 287–292, 687
- Low-density lipoprotein**
 oxidation, β -blockers 573–578
 peroxidation, myocardial ischaemia 29–34
- Lung**
 bronchial occlusion, pulmonary flow distribution 453–460
 granulocyte pool, pulmonary circulation 7–19*
- Lymphocytes**
 oxidative stress, elderly 447–452
- Lympho-mononuclear cells**
 cirrhosis, *N*^o-nitro-L-arginine methyl ester 637–643
- Magnetic resonance spectroscopy**
 muscle fatigue, hypoxaemia 279–286
- Major histocompatibility complex**
 Crohn's disease, genetic susceptibility 473–478*
- Malnutrition**
 tuberculosis, protein metabolism 321–331
- Malondialdehyde**
 antioxidant status, preterm infants 197–201
- Maternal undernutrition**
 hypertension, angiotensin-converting enzyme inhibitor 337–338, 373–381
- Matrix deposition**
 matrix metalloproteinases, atherosclerosis 103–110*
- Matrix metalloproteinases**
 vascular matrix remodelling, atherosclerosis 103–110*
- Membrane microviscosity**
 hypertension, calcium 79–85
- Menstruation**
 bone mineral density, pregnancy 405–412
- Metabolic alkalosis**
 bumetanide, natriuretic response 287–292, 687
- Metabolic effects**
 muscle fatigue, hypoxaemia 279–286
- Methacholine**
 cold exposure, asthma 525–529
- Methylation**
 protein, brain 677–685
- Microalbuminuria**
 angiotensin-converting enzyme, diabetes 165–173
- Microspheres**
 bronchial occlusion, pulmonary flow distribution 453–460
- Migrating motor complex**
 small intestine, 5-hydroxytryptamine 663–670
- Mitochondrion**
 ATP synthase, heart muscle 499–504
- N*^o-Monomethyl-L-arginine**
 nitric oxide synthase, glucose uptake 175–180
 erythrocytes, heart failure 3–4, 43–48

- Mucins**
gastric carcinoma 87–99
- Muscle**
ATP synthase, mitochondrion 499–504
- Muscle contractility**
preservation solutions, ischaemia 271–278
- Muscle fatigue**
³¹P magnetic resonance spectroscopy, hypoxaemia 279–286
- Muscle sympathetic activity**
adrenaline, isometric exercise 383–393
- Myocardial hypertrophy**
coronary arteries, nitric oxide 141–147
- Myocardial infarction**
adrenomedullin, natriuretic peptides 135–139
- Myocardial ischaemia**
thromboxane, atrial pacing 29–34
- Myoelectrical effects**
muscle fatigue, hypoxaemia 279–286
- Myogenic tone**
coronary arteries, acetylcholine 231–238
hypertension, nitric oxide 225–229
- Natriuretic peptides**
adrenomedullin, myocardial infarction 135–139
gene expression, heart failure 359–365
heart failure, renin–angiotensin–aldosterone system 591–599
hypertrophic cardiomyopathy, adrenomedullin 21–28
- Natriuretic response**
metabolic alkalosis, bumetanide 287–292, 687
- Necrotizing acute pancreatitis**
sodium taurocholate, zymogen granules 293–301
- Neurogenic inflammation**
diabetes, total skin blood flow 255–261
- Neuropeptide Y**
heart failure 591–599
- Neurovascular stimulation**
diabetes, nutritive capillary blood flow 255–261
- Neutrophil cathepsin G**
platelet–neutrophil adhesion, platelet P-selectin 437–445
- Neutrophil priming**
immune response, superoxide anions 461–471*
- Nitric oxide**
cardiopulmonary bypass, aprotinin 505–509
cirrhosis, peripheral vascular resistance 637–643
coronary arteries, endothelium-dependent relaxation 231–238
coronary arteries, myocardial hypertrophy 141–147
endothelium-dependent dilatation, Raynaud's disease 239–243
insulin sensitivity, blood flow 175–180
myogenic tone, hypertension 225–229
- Nitric oxide synthase**
glucose uptake, N^G-monomethyl-L-arginine 175–180
- N^G-Nitro-L-arginine**
coronary arteries, chronic ischaemic myocardial remodelling 141–147
- N^ω-Nitro-L-arginine**
myogenic tone, hypertension 225–229
- N^ω-Nitro-L-arginine methyl ester**
cirrhosis, nitric oxide synthase 637–643
- Nitroprusside**
baroreflex sensitivity, blood pressure 245–253
endothelial dysfunction, hypercholesterolaemia 129–134
- Noradrenaline**
endothelium-dependent vasodilatation, hypertension 601–607
hypertrophic cardiomyopathy, adrenomedullin 21–28
insulin resistance, hypertension 609–614
- Noradrenaline release**
muscle sympathetic activity, adrenaline 383–393
- Nuclear factor κB**
glucocorticoids, gene transcription 557–572*
- Nutrition**
haemodialysis, leptin 431–435
- Nutritive capillary blood flow**
neurovascular stimulation, diabetes 255–261
- Obesity**
leptin, haematopoiesis 633–636
leptin, haemodialysis 431–435
thermogenesis, cardiovascular response 121–127
- Octreotide**
insulin resistance, hypertension 609–614
portal hypertension, cirrhosis 367–371
portal hypertension, haemodynamics 645–650
- Orthostatic hypotension**
autonomic failure 347–352
- Osteogenesis**
colony forming units–fibroblastic, aging 549–555
- Osteoporosis**
aging, colony forming units–fibroblastic 549–555

- Oxidation
low-density lipoprotein, β -blockers 573–578
- Oxidative stress
diabetes, liver 623–632
lymphocytes, elderly 447–452
- Oxygen
cardiac surgery, plasma lipid 1, 35–41
- Oxygen free-radicals
diabetes, antioxidant enzymes 623–632
- Painful crisis
sickle cell disease, cooling 111–120
- Pancreas
oxidative stress, diabetes 623–632
- Pancreatitis
sodium taurocholate, zymogen granules 293–301
- Peripheral vascular resistance
nitric oxide, cirrhosis 637–643
- Peroxidation
myocardial ischaemia, low-density lipoprotein 29–34
- Phenylephrine
baroreflex sensitivity, blood pressure 245–253
- Phosphoinositide 3-kinase
neutrophil priming, inflammation 461–471*
- Phospholipase D
neutrophil priming, inflammation 461–471*
- Platelet–neutrophil adhesion
platelet P-selectin, neutrophil cathepsin G 437–445
- Platelet P-selectin
platelet–neutrophil adhesion, neutrophil cathepsin G 437–445
- Platelets
vascular endothelial growth factor, blood clotting 395–404
- Pneumonitis
bronchoalveolar lavage fluid, cytokeratins 531–535
- Polymorphism
haemorrhagic telangiectasia, adenosine deaminase deficiency 207–218*
- Portal hypertension
cirrhosis, octreotide 367–371
haemodynamics, octreotide 645–650
- Portal hypertensive gastropathy
cirrhosis, octreotide 367–371
- Portal vein stenosis
octreotide, hyperdynamic circulation 645–650
- Postprandial hypotension
gastric emptying, diabetes mellitus 65–70
- Postural hypotension
head-up tilt, temperature 493–498
- Potassium
blood specimens 101
- Power spectral analysis
diabetes, adolescents 615–621
heart rate variability, chronic fatigue syndrome 57–63
- Pregnancy
bone mineral density 405–412
- Prenatal exposure
glucocorticoids, hypertension 149–155
- Preservation solutions
muscle contractility, ischaemia 271–278
- Pressoreceptors
baroreflex sensitivity, hypertension 245–253
- Preterm infants
antioxidant status, lipid peroxidation 197–210
- Prostacyclin
myocardial ischaemia, atrial pacing 29–34
- Protein carboxymethylation
brain 677–685
- Protein diet
fetal exposure, hypertension 337–338, 373–381
- Protein metabolism
infection, acute phase proteins 413–423
tuberculosis, wasting 321–331
- Protein oxidative damage
elderly, oxidative stress 447–452
- Protein synthesis
sepsis, acute phase proteins 413–423
tuberculosis, wasting 321–331
- Proteinuria
diabetes, angiotensin-converting enzyme 165–173
renal tubular injury, lisinopril 425–430
- Proteoglycans
hypertrophic scar tissue, burns 541–547
- Proximal tubular hypercatabolism
proteinuria, lisinopril 425–430
- P-selectin
platelet–neutrophil adhesion, neutrophil cathepsin G 437–445
- Pulmonary arteriovenous malformations
linkage studies, haemorrhagic telangiectasia 207–218*
- Pulmonary circulation
granulocyte pool, lung 7–19*
- Pulmonary flow distribution
bronchial occlusion, blood gases 453–460
- Pulmonary inflammation
nitric oxide, aprotinin 505–509
- Pyridoxal-5'-phosphate
hypophosphatasia, alkaline phosphatase 203–206

- Raynaud's disease
nitric oxide, endothelium-dependent dilatation 239–243
- Reflex venoconstriction
hypertrophic cardiomyopathy, exercise-induced hypotension 335–336, 339–346
- Renal response
bumetanide 287–292, 687
- Renal tubular injury
proteinuria, lisinopril 425–430
- Renin–angiotensin–aldosterone system
heart failure, natriuretic peptides 591–599
- Respiratory disease
adenosine deaminase deficiency, polymorphism 207–218*
- Respiratory sinus arrhythmia
heart rate variability, aerobic exercise 579–584
- Retinol
diabetes, dietary supplements 189–195
- Retinopathy of prematurity
total antioxidant status, preterm infants 197–201
- Sarcoidosis
bronchoalveolar lavage fluid, cytokeratins 531–535
- Sepsis
protein synthesis, acute phase proteins 413–423
- Serotonin
small intestine, gastrointestinal motility 663–670
- Shear stress
endothelium-dependent dilatation, Raynaud's disease 239–243
- Sickle cell disease
cooling, vascular response 111–120
- Skeletal muscle
glucose metabolism, lipolysis 71–77
isometric exercise, cerebral blood flow 353–358
- Skin cooling
airway obstruction, asthma 525–529
- Small intestine
5-hydroxytryptamine, gastrointestinal motility 663–670
- Sodium excretion
bumetanide, metabolic alkalosis 287–292, 687
- Sodium taurocholate
zymogen granules, pancreatitis 293–301
- Spectrum analysis
baroreflex sensitivity, hypertension 245–253
- Stomach
mucins, tumour 87–99
- Strain-gauge plethysmography
deep venous thrombosis, duplex scanning 651–656
- Stroke volume
orthostatic hypotension, autonomic failure 347–352
- Stromelysin expression
atherosclerosis, polymorphism 103–110*
- Superoxide anions
neutrophil priming, immune response 461–471*
- Superoxide dismutase
diabetes, oxidative stress 623–632
oxidative stress, elderly 447–452
- Surface electromyogram
muscle fatigue, hypoxaemia 279–286
- Sympathetic denervation
exercise, blood pressure 5, 49–55
- Sympathetic nerves
adrenaline infusion, noradrenaline release 383–393
- Syncope
venous capacitance, hypertrophic cardiomyopathy 335–336, 339–346
- Temperature
haemodynamics, elderly 493–498
- Thermogenesis
adrenaline, energy expenditure 121–127
- Thiobarbituric acid-reactive substances
diabetes, oxidative stress 623–632
- Thrombin
platelet–neutrophil adhesion, platelet P-selectin 437–445
- Thromboxane
myocardial ischaemia, atrial pacing 29–34
- Tocopherols
diabetes, dietary supplements 189–195
endothelial dysfunction, hypercholesterolaemia 129–134
- Total skin blood flow
neurogenic inflammation, diabetes 255–261
- Transforming growth factor β
hypertrophic scar tissue, decorin 541–547
- Transoesophageal Doppler echocardiography
coronary flow reserve, dilated cardiomyopathy 485–492
- Transplantation
muscle contractility, preservation solutions 271–278
- Trimethylamino-diphenylhexatriene anisotropy
membrane microviscosity, erythrocytes 79–85
- Trypsinogen
zymogen granules, pancreatitis 293–301

- Tuberculosis
 undernutrition, anabolic block 321–331
- Tumour
 stomach, mucins 87–99
- Tumour growth
 dietary lipids, colon cancer 303–311
- Ulcerative colitis
 genetic linkage, Crohn's disease 473–478*
- Undernutrition
 tuberculosis, anabolic block 321–331
 tuberculosis, protein metabolism 321–331
- Upper limb venous thrombosis
 colour Doppler sonography 657–661
- Urokinase
 colonic epithelium, butyrate enema 671–676
- Vascular endothelial growth factor
 platelets, blood clotting 395–404
- Vascular matrix remodelling
 matrix metalloproteinases, atherosclerosis
 103–110*
- Vascular permeability factor
 platelets, blood clotting 395–404
- Vascular resistance
 blood pressure, autonomic failure 347–352
- Vascular response
 sickle cell disease, cooling 111–120
- Vascular smooth muscle
 myogenic tone, nitric oxide 225–229
- Vasoactive hormones
 heart failure, gene expression 359–365
- Vasoconstrictor
 endothelium-dependent relaxation,
 hypertension 231–238
- Vasodilatation
 hypertension, noradrenaline 601–607
- Vasopressin receptors
 deoxycorticosterone acetate-salt hypertension
 517–523
- Venous capacitance
 hypotension, hypertrophic cardiomyopathy
 335–336, 339–346
- Venous thrombosis
 colour Doppler sonography 657–661
- Vitamin B₆
 alkaline phosphatase, hypophosphatasia
 203–206
- Vitamin E
 endothelial dysfunction, hypercholesterolaemia
 129–134
- Wasting
 tuberculosis, protein metabolism 321–331
- Zymogen granules
 enzyme content, pancreatitis 293–301